{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:27:01Z","timestamp":1789165621803,"version":"build-2803163510"},"reference-count":148,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2024YFFK0346; 2022YFS0623; 025YFHZ0154"],"award-info":[{"award-number":["2024YFFK0346; 2022YFS0623; 025YFHZ0154"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Breast cancer is a highly heterogeneous malignancy with multiple molecular subtypes and variable treatment responses. Despite advances in endocrine therapy, HER2-targeted therapy, chemotherapy, and immunotherapy, treatment resistance and disease recurrence remain major clinical challenges. There is growing evidence that transcriptional plasticity and enhancer relinking contribute to tumor progression and treatment adaptation, highlighting the powerful role of epigenetic regulators. CREB-binding protein (CBP) and E1A-associated protein p300 (EP300) are transcriptional coactivators that regulate breast cancer enhancer activity and lineage-specific gene expression. Emerging research suggests that CBP\/p300 is more of a context-dependent vulnerability point than a universal carcinogenic driver. ER-positive tumors exhibit a strong dependence on CBP\/p300-mediated transcriptional programs, while the triple-negative breast cancer subgroup, including androgen receptor-positive and immunosuppressive tumors, may rely on CBP\/p300-dependent signaling to maintain survival and treatment resistance. This is in contrast to their role in HER2-positive breast cancer. This review summarizes the biological functions of CBP\/p300 in breast cancer and discusses subtype-specific vulnerability, biomarker-directed patient stratification, drug resistance mechanisms, rational combination strategies, and current translational challenges, emphasizing the need for precise treatment of breast cancer.<\/jats:p>","DOI":"10.3390\/molecules31142426","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:16:28Z","timestamp":1783689388000},"page":"2426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Mechanism of Action and Efficacy of CBP\/p300 Inhibitors in Different Subtypes of Breast Cancer"],"prefix":"10.3390","volume":"31","author":[{"given":"Yue","family":"Yang","sequence":"first","affiliation":[{"name":"Institute for Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, No. 1 Section 1, Xiang Lin Road, Longmatan District, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute for Cancer Medicine, School of Basic Medical Sciences, Southwest Medical University, No. 1 Section 1, Xiang Lin Road, Longmatan District, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8557-6521","authenticated-orcid":false,"given":"Yan","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute for Cancer Medicine, School of Basic Medical Sciences, Southwest Medical University, No. 1 Section 1, Xiang Lin Road, Longmatan District, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4704-3163","authenticated-orcid":false,"given":"Lin","family":"Gan","sequence":"additional","affiliation":[{"name":"Institute for Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, No. 1 Section 1, Xiang Lin Road, Longmatan District, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The globocan 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis","volume":"114","author":"Pedersen","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1245\/s10434-014-4279-0","article-title":"The 2014 society of surgical oncology Susan G. Komen for the cure symposium: Triple-negative breast cancer","volume":"22","author":"Newman","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). Breast cancer\u2014Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014An updated review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_7","first-page":"36","article-title":"Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: From molecular insights to translational perspectives","volume":"8","author":"Saha","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00018-026-06171-8","article-title":"Game of clones: Decipher lineage plasticity in hormone-driven cancers","volume":"83","author":"Leonita","year":"2026","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","first-page":"73","article-title":"Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer","volume":"6","author":"Shuai","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11010-025-05415-8","article-title":"Navigating the complexities of epigenetic dysregulation in breast cancer and its implication in therapeutic interventions: A comprehensive overview","volume":"481","author":"Ravindran","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Aristorena-Arruabarrena, A., and Toska, E. (2022). Epigenetic mechanisms influencing therapeutic response in breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.924808"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e250125","DOI":"10.1530\/ERC-25-0125","article-title":"Epigenetic therapeutics: Reprogramming triple-negative breast cancer into responsive subtypes","volume":"32","author":"Ramadan","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107205","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102948","DOI":"10.1016\/j.sbi.2024.102948","article-title":"Short circuit: Transcription factor addiction as a growing vulnerability in cancer","volume":"89","author":"Davies","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110715","DOI":"10.1016\/j.jbc.2025.110715","article-title":"The complex network of p300\/CBP regulation: Interactions, post-translational modifications, and therapeutic implications","volume":"301","author":"McIntyre","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115544","DOI":"10.1016\/j.celrep.2025.115544","article-title":"DUX-mediated configuration of p300\/CBP drives minor zygotic genome activation independent of its catalytic activity","volume":"44","author":"Xiao","year":"2025","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Masci, D., Puxeddu, M., Silvestri, R., and Regina, G.L. (2024). Targeting CBP and p300: Emerging anticancer agents. Molecules, 29.","DOI":"10.3390\/molecules29194524"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12967-025-07053-6","article-title":"CBP\/p300, a promising therapeutic target for prostate cancer","volume":"23","author":"Xu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10565-024-09984-0","article-title":"The important role of the histone acetyltransferases p300\/CBP in cancer and the promising anticancer effects of p300\/CBP inhibitors","volume":"41","author":"Wu","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Waddell, A.R., Huang, H.J., and Liao, D.Q. (2021). CBP\/p300: Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers. Cancers, 13.","DOI":"10.3390\/cancers13122872"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e182621","DOI":"10.1172\/jci.insight.182621","article-title":"CREB-binding protein\/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer","volume":"9","author":"Yuan","year":"2024","journal-title":"Jci Insight"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108636","DOI":"10.1016\/j.pharmthera.2024.108636","article-title":"Characteristics of anticancer activity of CBP\/p300 inhibitors\u2014Features of their classes, intracellular targets and future perspectives of their application in cancer treatment","volume":"257","author":"Strachowska","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17501911.2024.2447807","article-title":"Dysregulation of the p300\/CBP histone acetyltransferases in human cancer","volume":"17","author":"Xu","year":"2025","journal-title":"Epigenomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"116130","DOI":"10.1016\/j.biopha.2024.116130","article-title":"Protein lysine acetyltransferase CBP\/p300: A promising target for small molecules in cancer treatment","volume":"171","author":"Gou","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10555-023-10103-4","article-title":"Oncogenic super-enhancers in cancer: Mechanisms and therapeutic targets","volume":"42","author":"Bacabac","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release","volume":"81","author":"Narita","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104826","DOI":"10.1016\/j.critrevonc.2025.104826","article-title":"Super enhancers as drivers of hallmarks of cancer: From oncogene activation to metastatic progression","volume":"214","author":"Fan","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-023-00949-7","article-title":"FT-6876, a potent and selective inhibitor of CBP\/p300, is active in preclinical models of androgen receptor-positive breast cancer","volume":"18","author":"Caligiuri","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Song, X.Z., Zhang, C.W., Zhao, M.K., Chen, H., Liu, X., Chen, J.W., Lonard, D.M., Qin, L., Xu, J.M., and Wang, X.S. (2015). Steroid receptor Coactivator-3 (SRC-3\/AIB1) as a novel therapeutic target in triple negative breast cancer and its inhibition with a phospho-bufalin prodrug. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140011"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1038\/emboj.2011.414","article-title":"Erratum to: Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer","volume":"30","author":"Zwart","year":"2011","journal-title":"EMBO J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/acschembio.4c00438","article-title":"Functional investigations of p53 acetylation enabled by heterobifunctional molecules","volume":"19","author":"Chen","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Waddell, A., Mahmud, I., Ding, H.C., Huo, Z.G., and Liao, D.Q. (2021). Pharmacological inhibition of CBP\/p300 blocks estrogen receptor alpha (ER\u03b1) function through suppressing enhancer H3K27 acetylation in luminal breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13112799"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17112","DOI":"10.1038\/s41598-023-44412-z","article-title":"The histone acetyl transferases CBP and p300 regulate stress response pathways in synovial fibroblasts at transcriptional and functional levels","volume":"13","author":"Gabathuler","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: A new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E5335","DOI":"10.1073\/pnas.1703105114","article-title":"Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation","volume":"114","author":"Park","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1021\/ja412434f","article-title":"Discovery and optimization of small-molecule ligands for the CBP\/p300 bromodomains","volume":"136","author":"Hay","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","article-title":"Enhancer activity requires CBP\/P300 bromodomain-dependent histone H3K27 acetylation","volume":"24","author":"Raisner","year":"2018","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.celrep.2019.03.008","article-title":"Regulation of tumor-associated myeloid cell activity by CBP\/EP300 bromodomain modulation of H3K27 acetylation","volume":"27","author":"Nagata","year":"2019","journal-title":"Cell Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s42003-020-0898-0","article-title":"Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha","volume":"3","author":"Gao","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1038\/s41467-019-12861-8","article-title":"E2F1 acetylation directs p300\/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair","volume":"10","author":"Manickavinayaham","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41419-021-03761-1","article-title":"CBP\/p300 HAT maintains the gene network critical for \u03b2 cell identity and functional maturity","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cancers7010030","article-title":"p53 acetylation: Regulation and consequences","volume":"7","author":"Reed","year":"2014","journal-title":"Cancers"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1038\/s41467-024-47102-0","article-title":"Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300\/CBP inhibition","volume":"15","author":"Shendy","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/1535-7163.MCT-12-0930","article-title":"Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents","volume":"12","author":"Yang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2533\/chimia.2025.137","article-title":"Recent advances in CBP\/EP300 degraders","volume":"79","author":"Palaferri","year":"2025","journal-title":"Chimia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Ojeda","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"107427","DOI":"10.1016\/j.bioorg.2024.107427","article-title":"Design, synthesis and biological evaluation of new RNF126-based p300\/CBP degraders","volume":"148","author":"Lei","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood-2024-207964","article-title":"Activity of orally available CBP\/p300 fegraders in pre-clinical models of multiple myeloma","volume":"144","author":"Tiwari","year":"2024","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1021\/acs.jmedchem.4c01100","article-title":"Discovery of a highly potent PROTAC degrader of p300\/CBP proteins for the treatment of enzalutamide-resistant prostate cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader BRD4: Tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Spriano","year":"2020","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13525","article-title":"Targeting both BET and CBP\/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in Multiple Myeloma","volume":"106","author":"Ryan","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/path.6280","article-title":"Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer","volume":"263","author":"Choo","year":"2024","journal-title":"J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"viii140","DOI":"10.1093\/annonc\/mdy279.416","article-title":"NEO2734: A novel potent oral dual BET and P300\/CBP inhibitor","volume":"29","author":"Giles","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"Gne-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102255","DOI":"10.1016\/j.cbpa.2022.102255","article-title":"KATs off: Biomedical insights from lysine acetyltransferase inhibitors","volume":"72","author":"Whedon","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2024.01.005","article-title":"Small-molecule CBP\/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response","volume":"57","author":"Jaschke","year":"2024","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","article-title":"EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma","volume":"12","author":"Durbin","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/MCB.26.3.789-809.2006","article-title":"Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development","volume":"26","author":"Kasper","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1387\/ijdb.10610021","article-title":"Developmentally regulated expression of the transcriptional cofactors\/histone acetyltransferases CBP and p300 during mouse embryogenesis","volume":"43","author":"Partanen","year":"1999","journal-title":"Int. J. Dev. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1038\/s41467-026-71499-5","article-title":"CBP\/p300 is critical for the expansion and maintenance of functional pancreatic \u03b1 cell mass","volume":"17","author":"Wang","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"TPS5085","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5085","article-title":"The Courage study: A first-in-human phase 1 study of the CBP\/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer","volume":"39","author":"Armstrong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1101\/gad.302182.117","article-title":"Dynamic assembly and activation of estrogen receptor \u03b1 enhancers through coregulator switching","volume":"31","author":"Murakami","year":"2017","journal-title":"Genes Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/msb.2011.59","article-title":"Cellular reprogramming by the conjoint action of ER\u03b1, FOXA1, and GATA3 to a ligand-inducible growth state","volume":"7","author":"Kong","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"ref_68","first-page":"26","article-title":"Emerging role of pioneer transcription factors in targeted ER\u03b1 positive breast cancer","volume":"2","author":"Pavithran","year":"2021","journal-title":"Explor. Target. Anti-Tum. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2016.12.020","article-title":"RNA binding to CBP stimulates histone acetylation and transcription","volume":"168","author":"Bose","year":"2017","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-21-2576","article-title":"Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41467-017-01864-y","article-title":"Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance","volume":"8","author":"Martin","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1038\/s41388-018-0284-2","article-title":"Proteomic profiling identifies key coactivators utilized by mutant ER\u03b1 proteins as potential new therapeutic targets","volume":"37","author":"Gates","year":"2018","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"GarciaMartinez","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2300124","DOI":"10.1200\/PO.23.00124","article-title":"Comprehensive analysis identifies variability in PI3K pathway alterations in triple-negative breast cancer subtypes","volume":"8","author":"Basho","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1038\/s41598-025-92281-5","article-title":"Author correction: Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","article-title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer","volume":"56","author":"Taifour","year":"2023","journal-title":"Immunity"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Qutami, F.A., AlHalabi, W., Vijayakumar, A., Rawat, S.S., Mossa, A.H., Jayakumar, M.N., Samreen, B., and Hachim, M.Y. (2024). Characterizing the inflammatory profile of neutrophil-rich triple-negative breast cancer. Cancers, 16.","DOI":"10.3390\/cancers16040747"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1038\/s41388-025-03417-w","article-title":"Therapeutic targeting of the p300\/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy","volume":"44","author":"Liu","year":"2025","journal-title":"Oncogene"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41401-021-00631-6","article-title":"The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth","volume":"43","author":"Xu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"115015","DOI":"10.1016\/j.celrep.2024.115015","article-title":"Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Strachowska, M., Gronkowska, K., Michlewska, S., and Robaszkiewicz, A. (2021). CBP\/p300 bromodomain inhibitor-I-CBP112 declines transcription of the key ABC transporters and sensitizes cancer cells to chemotherapy drugs. Cancers, 13.","DOI":"10.3390\/cancers13184614"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"116116","DOI":"10.1016\/j.ejmech.2023.116116","article-title":"Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer","volume":"266","author":"Lai","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","author":"Luo","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1182\/blood-2025-5735","article-title":"Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma","volume":"146","author":"Shome","year":"2025","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.7150\/thno.36338","article-title":"CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1\/P50","volume":"9","author":"Chi","year":"2019","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"115798","DOI":"10.1016\/j.biopha.2023.115798","article-title":"I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs","volume":"168","author":"Strachowska","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Schlam, I., Tarantino, P., and Tolaney, S.M. (2022). Overcoming resistance to HER2-directed therapies in breast cancer. Cancers, 14.","DOI":"10.3390\/cancers14163996"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e2309424","DOI":"10.1002\/advs.202309424","article-title":"Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer","volume":"11","author":"Duan","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19516","DOI":"10.1038\/s41598-023-46460-x","article-title":"Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells","volume":"13","author":"Rojhannezhad","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108780","DOI":"10.1016\/j.isci.2024.108780","article-title":"Identification of somatic mutation-driven enhancers and their clinical utility in breast cancer","volume":"27","author":"Zhao","year":"2024","journal-title":"iScience"},{"key":"ref_93","first-page":"261","article-title":"\u03b2-catenin promotes resistance to trastuzumab in breast cancer cells through enhancing interaction between HER2 and SRC","volume":"70","author":"Hao","year":"2023","journal-title":"Acta Biochim. Pol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Higuchi, Y., Teo, J.L., Yi, D., and Kahn, M. (2025). Safely targeting cancer, the wound that never heals, utilizing CBP\/beta-catenin antagonists. Cancers, 17.","DOI":"10.3390\/cancers17091503"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1083\/jcb.149.2.249","article-title":"The transcriptional coactivator CBP interacts with \u03b2-catenin to activate gene expression","volume":"149","author":"Takemaru","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17501911.2025.2460900","article-title":"A narrative review of epigenetic marker in H3K27ac and its emerging potential as a therapeutic target in cancer","volume":"17","author":"Zhu","year":"2025","journal-title":"Epigenomics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11670-011-0201-5","article-title":"High Expression of p300 in Human Breast Cancer Correlates with Tumor Recurrence and Predicts Adverse Prognosis","volume":"23","author":"Xiao","year":"2011","journal-title":"Chin. J. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41065-025-00630-1","article-title":"A combined transcriptomic, epigenetic, and functional analysis identifies novel biomarkers in breast cancer","volume":"163","author":"Gari","year":"2025","journal-title":"Hereditas"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41698-024-00529-6","article-title":"Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets","volume":"8","author":"Lusby","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12032-025-02905-z","article-title":"Epigenetic dysregulation in cancer: Mechanisms, diagnostic biomarkers and therapeutic strategies","volume":"42","author":"Imran","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Zeng, Q.M., Wang, K., Zhao, Y.X., Ma, Q.Z., Chen, Z.N., and Huang, W. (2023). Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification. Biomolecules, 13.","DOI":"10.3390\/biom13030417"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-007-9737-y","article-title":"The prognostic significance of steroid receptor co-regulators in breast cancer: Co-repressor NCOR2\/SMRT is an independent indicator of poor outcome","volume":"110","author":"Green","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1541-7786.MCR-18-0719","article-title":"CREBBP\/EP300 bromodomain inhibition affects the proliferation of AR-positive breast cancer cell lines","volume":"17","author":"Sarmentero","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12967-025-06200-3","article-title":"Acetylation suppresses breast cancer progression by sustaining CLYBL stability","volume":"23","author":"Deng","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Liu, X., Gillis, N., Jiang, C., McCofie, A., Shaw, T.I., Tan, A.C., Zhao, B., Wan, L.X., Duckett, D.R., and Teng, M.X. (2024). An Epigenomic fingerprint of human cancers by landscape interrogation of super enhancers at the constituent level. PLoS Comput. Biol., 20.","DOI":"10.1371\/journal.pcbi.1011873"},{"key":"ref_106","first-page":"e122225","article-title":"Transcriptional targeting of oncogene addiction in medullary thyroid cancer","volume":"3","author":"Valenciaga","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"baad022","DOI":"10.1093\/database\/baad022","article-title":"CenhANCER: A comprehensive cancer enhancer database for primary tissues and cell lines","volume":"2023","author":"Luo","year":"2023","journal-title":"Database"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"BommiReddy, A., ParkChouinard, S., Mayhew, D.N., Terzo, E., Hingway, A., Steinbaugh, M.J., Wilson, J.E., Sims, R.J., and Conery, A.R. (2022). CREBBP\/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262378"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-025-02342-6","article-title":"Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","article-title":"Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"21639","DOI":"10.1002\/cam4.6718","article-title":"Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer","volume":"12","author":"Lin","year":"2023","journal-title":"Cancer Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"109366","DOI":"10.1016\/j.isci.2024.109366","article-title":"\u0394Np63 regulates MDSC survival and metabolism in triple-negative breast cancer","volume":"27","author":"Kim","year":"2024","journal-title":"iScience"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coph.2017.05.006","article-title":"Epigenetic modulation in cancer immunotherapy","volume":"35","author":"Gallagher","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-22-0543","article-title":"Dynamic changes in the NK-, neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy-resistant early breast cancers","volume":"28","author":"Gazinska","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41467-022-34570-5","article-title":"Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer","volume":"14","author":"Taylor","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1016\/j.apsb.2024.04.009","article-title":"Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-018-2154-8","article-title":"Diacylglycerol kinase \u03b1 inactivation is an integral component of the costimulatory pathway that amplifies TCR signals","volume":"67","author":"Ogando","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2296713","DOI":"10.1080\/2162402X.2023.2296713","article-title":"Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer","volume":"13","author":"Heger","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41540-025-00549-3","article-title":"Single-cell transcriptomic profiling of immune landscape in triple-negative breast cancer during neoadjuvant chemotherapy","volume":"11","author":"Patysheva","year":"2025","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41589-023-01320-7","article-title":"Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition","volume":"19","author":"Bishop","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"ref_122","first-page":"1106","article-title":"Network rewiring, adaptive resistance and combating strategies in breast cancer","volume":"2","author":"Cremers","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2025.03.034","article-title":"The clinical-grade CBP\/p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs","volume":"233","author":"Wang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"108744","DOI":"10.1016\/j.celrep.2021.108744","article-title":"An acetyl-histone vulnerability in PI3K\/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors","volume":"34","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/s41375-020-0706-3","article-title":"Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML","volume":"34","author":"Kahl","year":"2020","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41388-020-1301-9","article-title":"Therapeutic targeting of p300\/CBP HAT domain for the treatment of NUT midline carcinoma","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ijc.28341","article-title":"Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K\/Akt\/\u03b2-catenin\/CBP pathway","volume":"134","author":"He","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Manegold, P., Lai, K.K.Y., Wu, Y.F., Teo, J.L., Lenz, H.J., Genyk, Y.S., Pandol, S.J., Wu, K., Lin, D.P., and Chen, Y.B. (2018). Differentiation Therapy Targeting the \u03b2-Catenin\/CBP Interaction in Pancreatic Cancer. Cancers, 10.","DOI":"10.3390\/cancers10040095"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/0008-5472.CAN-20-1847","article-title":"Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth","volume":"81","author":"Miller","year":"2021","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2024.10.015","article-title":"ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion","volume":"37","author":"Zhu","year":"2024","journal-title":"Cell Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41419-024-06951-9","article-title":"Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Mogol, A.N., Yoo, J.Y., Arredondo-Eve, A., Goel, M., Dutton, D.J., Schane, C.P., Lam, A., Dutta, D., Barnick, B., and Erdogan, E.D. (npj Breast Cancer, 2025). ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target, npj Breast Cancer, Online ahead of print.","DOI":"10.1101\/2025.09.23.678089"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/nar\/gky1306","article-title":"The LIM protein Ajuba recruits DBC1 and CBP\/p300 to acetylate ER\u03b1 and enhances ER\u03b1 target gene expression in breast cancer cells","volume":"47","author":"Xu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1073\/pnas.97.3.1020","article-title":"CBP\/p300 interact with and function as transcriptional coactivators of BRCA1","volume":"97","author":"Pao","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e2025840118","DOI":"10.1073\/pnas.2025840118","article-title":"Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation","volume":"118","author":"Zhou","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cac2.12546","article-title":"Converting \u201ccold\u201d to \u201chot\u201d: Epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"103401","DOI":"10.1016\/j.critrevonc.2021.103401","article-title":"Corrigendum to \u201cThe cyclin-dependent kinases pathway as a target for prostate cancer treatment: Rationale and future perspectives\u201d [Crit. Rev. Oncol. Hematol. 157 (January) (2021) 103199]","volume":"164","author":"Brighi","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-20-2828","article-title":"HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4\/6 Inhibitor Resistance in Cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e181062","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"110180","DOI":"10.1016\/j.isci.2024.110180","article-title":"A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity","volume":"27","author":"Sellars","year":"2024","journal-title":"iScience"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"117959","DOI":"10.1016\/j.ejmech.2025.117959","article-title":"Medicinal chemistry approaches to the discovery and development of p300\/CBP inhibitors for cancer therapy","volume":"297","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"112861","DOI":"10.1016\/j.ejmech.2020.112861","article-title":"Current development of CBP\/p300 inhibitors in the last decade","volume":"209","author":"He","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/14\/2426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:10:57Z","timestamp":1784088657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/14\/2426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":148,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["molecules31142426"],"URL":"https:\/\/doi.org\/10.3390\/molecules31142426","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}